Inhibition of cell-cell binding by lipid assemblies
First Claim
Patent Images
1. A composition for inhibiting the binding between a first cell having a receptor comprising selectin and a second cell having a ligand for said receptor, comprising one or more lipid assemblies, wherein said one or more lipid assembies comprise:
- a) lipid monomers wherein substantially all of said lipid monomers are unpolmerized;
b) one or more surface exposed negatively charged oxyacid groups attached to said one or more lipid assemblies and, wherein said oxyacid groups are selected from the group consisting of carboxyl groups and groups of the form (XOn)(O−
)p, wherein n+p>
2 and X is an atom capable of binding three or more oxygen atoms, wherein said one or more surface exposed negatively charged oxyacid groups meets the anionic binding requirement of said receptor; and
c) one or more surface exposed carbohydrates which selectively binds to said receptor.
3 Assignments
0 Petitions
Accused Products
Abstract
This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.
80 Citations
39 Claims
-
1. A composition for inhibiting the binding between a first cell having a receptor comprising selectin and a second cell having a ligand for said receptor, comprising one or more lipid assemblies, wherein said one or more lipid assembies comprise:
-
a) lipid monomers wherein substantially all of said lipid monomers are unpolmerized;
b) one or more surface exposed negatively charged oxyacid groups attached to said one or more lipid assemblies and, wherein said oxyacid groups are selected from the group consisting of carboxyl groups and groups of the form (XOn)(O−
)p, wherein n+p>
2 and X is an atom capable of binding three or more oxygen atoms, wherein said one or more surface exposed negatively charged oxyacid groups meets the anionic binding requirement of said receptor; and
c) one or more surface exposed carbohydrates which selectively binds to said receptor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 16, 29, 30, 31, 32, 33, 34, 35, 36, 38)
-
-
8. A method for inhibiting the binding between a first cell having a receptor comprising selectin, and a second cell having a ligand for said receptor, comprising:
-
a) providing;
i) a sample containing said first cell and said second cell; and
ii) a lipid monomer assembly, wherein substantially all of said lipid monomers are unpolymerized, one or more surface exposed negatively charged oxyacid groups selected from the group consisting of carboxyl groups and groups of the form (XOn)(O−
)p, wherein n+p>
2 and X is an atom capable of binding three or more oxygen atoms, and one or more surface exposed carbohydrates which selectively binds to said receptor; and
b) exposing said lipid assembly to said first cell. - View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 21, 22, 23, 24, 25, 26, 27, 28, 39)
-
- 17. A composition for inhibiting the binding between a first cell having a receptor comprising selectin and a second cell having a ligand for said receptor, comprising one or more lipid monomers, wherein substantially all of said lipid monomers are unpolymerized, one or more surface exposed carboxyl groups attached to said one or more lipid monomers and which meets the anionic binding requirements of said receptor, and one or more surface exposed carbohydrates which selectively binds to said receptor, wherein said one or more surface exposed carbohydrates is selected from the group consisting of sulfated fucooligosaccharide, sialylated fucooligosaccharide, sialylated fucooligosaccharide analog, maltose, lactose, sulfated lactose, sialic acid, fucose, monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and glycopeptides.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeLigoCyte Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited), Regents of the University of California (University of California)
-
Original AssigneeRegents of the University of California (University of California)
-
InventorsBargatze, Robert F., Nagy, Jon O.
-
Primary Examiner(s)Kishore, Gollamudi S.
-
Application NumberUS09/032,377Time in Patent Office1,180 DaysField of Search424/450, 424/812, 436/829, 514/25, 514/42, 514/53, 514/54, 514/61, 435/7.1, 435/7.2US Class Current424/450CPC Class CodesA61K 9/1273 Polymersomes; Liposomes wit...Y10S 424/812 Liposome comprising an anti...
